Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Szukaj Study Connect

Not Yet Recruiting

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors - CA238-0001

Zaktualizowano: 9 grudzień, 2024   |   ClinicalTrials.gov

Wydruk podsumowania

BIERZESZ POD UWAGĘ TO BADANIE?
Wydrukuj tę stronę i przewodnik po badaniu, aby pomóc sobie w rozmowie z lekarzem.
Skorzystaj z Przewodnika po badaniu, aby dowiedzieć się o procesie badań klinicznych. Zapoznaj się z kluczowymi czynnikami, które należy wziąć pod uwagę przed podjęciem decyzji i zanotuj pytania, aby zadać je personelowi medycznemu.

Szczegóły badania

  • Phase 1/Phase 2

    Etap

  • Płeć

  • 18+

    Zakres wieku

  • 6

    Lokalizacje

  • Not Yet Recruiting

Opcje leczenia

Grupy badania
PRZYPISANA INTERWENCJA
Experimental: Part 1A
Drug: BMS-986490
Experimental: Part 1B
Drug: BMS-986490, Bevacizumab
Experimental: Part 2A - Colorectal Cancer (CRC)
Drug: BMS-986490
Experimental: Part 2A - Non-Small Cell Lung Cancer/Gastric Cancer (NSCLC/GC)
Drug: BMS-986490
Experimental: Part 2B
Drug: BMS-986490, Bevacizumab

Kluczowe kryteria kwalifikacyjne

Inclusion Criteria: - Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1. - CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:. i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated). - NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:. i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease. ii) Progressed on at least 2 prior lines of therapy, iii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available. - GC: Part 2A-NSCLC/GC, 2L+ GC:. i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy). ii) ECOG performance status of 0 or 1. Exclusion Criteria: - History of anaphylactic reactions to irinotecan and/or bevacizumab. - Previously received therapy targeting CEACAM5. - Grade ≥ 3 ILD/pneumonitis. - Other protocol-defined Inclusion/Exclusion criteria apply.